MTVA - metaviatx.com Debt to Book Capitalization Ratio

Corporate company logo of MetaVia, Inc. (MTVA)

How can environmental impact be minimized in MetaVia Inc (MTVA) neurobiology laboratories? The history of the total debt-to-equity ratio demonstrates financing dynamics, where 0.03 represents the latest metric reading. Stability is provided by grants for scientists developing dementia medications, while the lack of current profit is offset by investments tied to clinical development stages.

MetaVia Inc. (MTVA) - Debts to Book Value from 11/30/2024 to 10/27/2026
Flagship merchandise of MetaVia Inc.

A fundamental stress test of assets requires an assessment of the capital structure's resilience to external shocks. MetaVia Inc (MTVA) invests in high-tech precision medicine to combat severe metabolic pathologies. By analyzing the total debt-to-equity chart, an investor determines the proportion of borrowed funds relative to equity. Reducing this leverage minimizes financial risks; however, an excessive avoidance of credit may slow the development pace of innovative treatment methods.

Competitors of MetaVia Inc (MTVA)

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|XENE (Xenon Corp) - Debts to Book Value|Debt to Book Capitalization Ratio VKTX|Debt to Book Value supernus.com|Catalyst Pharmaceuticals, Inc. - Debts to Book Capitalization|Debts to Book Value Denali DNLI|Debt to Book Value Harmony Pharma (HRMY)|Debt to Book Capital Biohaven Corp BHVN|Amylyx Pharmaceuticals - Debts to Book Capitalization|trevitherapeutics.com (TRVI) - Debts to Book Capitalization|Praxis Precision Medicines, Inc. (PRAX) - Debt to Book Value|Anavex (AVXL) - Debt to Book Capitalization Ratio|CBLL: Debts to Book Capitalization|Debts to Net Assets prothena.com|Debts to Book Capitalization ALEC|Debts to Book Capitalization annexonbio.com ANNX|Debt to Book Value Omeros|Debt to Net Assets Ratio Neurogene Inc NGNE|Debts to Book Capitalization ACIU (AC Immune Corp)|VYGR: Debts to Net Assets|Debt to Book Capitalization Ratio Neumora Therapeutics|scilexholding.com (SCLX) - Debt to Book Value Ratio|Debts to Book Capitalization TVGN|Debt to Book Value ACOG|Debt to Book Capitalization Ratio CGTX (Cognition Therapeutics)|Debt to Book Value Inhibikase Pharma IKT|Debt to Book Value Cassava Sciences, Inc. (SAVA)|ASRT - Debt to Book Capital|COYA - Debt to Book Value|VTGN - Debt to Book Capitalization Ratio|OVID: Debts to Book Capitalization|ABOS (Acumen Pharmaceuticals, Inc) - Debts to Book Capitalization|Debt to Book Capitalization Ratio CervoMed Inc. (CRVO)|Debt to Book Value Ratio Alterity Therapeutics Ltd|Clene Inc. - Debts to Book Capitalization|Debts to Book Value pepgen.com PEPG|Debt to Book Value JUNS (Jupiter Neurosciences Inc)|Relmada Corp - Debts to Book Capitalization|Debt to Book Capitalization Ratio Annovis Bio, Inc. (ANVS)|GRCE: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio AIFF|KLTO (Klotho Neurosciences) - Debts to Book Value|Debt to Book Capitalization Ratio NRSN|Debt to Book Value Reviva Pharmaceuticals, Inc.|NeurAxis, Inc. - Debts to Book Capitalization|Debts to Book Value heliusmedical.com HSDT|Debt to Book Value Passage Bio (PASG)|Debt to Book Capital Neuphoria Therapeutics, Inc. NEUP|Minerva Neurosciences Corp - Debts to Book Capitalization|Athira Pharma Corp (ATHA) - Debts to Book Capitalization|Addex Therapeutics (ADXN) - Debt to Book Value|Alzamend Neuro (ALZN) - Debt to Book Capitalization Ratio|CYCN: Debts to Book Capitalization|Debts to Net Assets Protagenic|Debts to Book Capitalization KTTA|Debts to Book Capitalization cortigent.com CRGT|Debt to Book Value Avenue Therapeutics|Debt to Net Assets Ratio brainstorm-cell.com BCLI|Debts to Book Capitalization CARA (Cara Therapeutics)|CHRO: Debts to Net Assets|Debt to Book Capitalization Ratio eliemtx.com|Intra-Cellular Therapies, Inc. (ITCI) - Debt to Book Value Ratio|Debts to Book Capitalization LBPH|Debt to Book Value MRNS|Debt to Book Capitalization Ratio NKGN (NKGen Biotech)|Debt to Book Value NeuroBo Pharmaceuticals Inc NRBO|Debt to Book Value Sage Therapeutics, Inc (SAGE)|SNPX - Debt to Book Capital|TRVN - Debt to Book Value|VIGL - Debt to Book Capitalization Ratio|WENA: Debts to Book Capitalization|CERE (Cerevel Therapeutics Inc) - Debts to Book Capitalization